My Library

University LibraryCatalogue

LEADER 00000cam a2200421 a 4500 
008    060107s2006    njuc     b    000 0 eng   
015    GBA655214|2bnb 
019 1  40442937|z41044404 
020    9780691126142|q(pbk. : acid-free paper) :|c£11.95 
020    0691126143|q(pbk. : acid-free paper) :|c£11.95 
039    DA 
       Changes made will be lost. Metadata Team. 
040    StDuBDS|beng|dVU 
042    ukscp 
043    n-us-ca 
082 04 338.7660609794|222 
082 04 338.76606|222 
100 1  Rabinow, Paul. 
245 12 A machine to make a future :|bbiotech chronicles /|cPaul 
       Rabinow and Talia Dan-Cohen ; with a new afterword by the 
250    [New ed.]. 
260    Princeton, N.J. ;|aOxford :|bPrinceton University Press,
       |c2006, c2005. 
300    215 p. :|bports. ;|c24 cm. 
500    First published: 2005. 
500    "...with a new afterword by the authors, 2006".--T.p. 
504    Includes bibliographical references. 
520    "This book represents a remarkably original look at the 
       present and possible future of biotechnology research in 
       the wake of the mapping of the human genome. The central 
       tenet of Celera Diagnostics--the California biotech 
       company whose formative work during 2003 is the focus of 
       the book--is that the emergent knowledge about the genome,
       with its profound implications for human health, can now 
       be turned into a powerful diagnostic apparatus--one that 
       will yield breakthrough diagnostic and therapeutic 
       products (and, potentially, profit). Celera's efforts--
       assuming they succeed--may fundamentally reshape the 
       fabric of how health and health care are understood, 
       practiced, and managed. Presenting a series of interviews 
       with all of the key players in Celera Diagnostics, Paul 
       Rabinow and Talia Dan-Cohen open a fascinating window on 
       the complexity of corporate scientific innovation. This 
       marks a radical departure from other books on the biotech 
       industry by chronicling the vicissitudes of a project 
       during a finite time period, in the words of the actors 
       themselves. Ultimately, the authors conclude, Celera 
       Diagnostics is engaged in a future characterized not by 
       geniuses and their celebrated discoveries but by a largely
       anonymous and widely distributed profusion of data and 
       results--a "machine to make a future." In their new 
       afterword, Rabinow and Dan-Cohen revisit Celera 
       Diagnostics as its mighty machine grinds along, wondering,
       along with the scientists, "what constitutes success and 
       what constitutes failure?" The pathos of the situation 
       turns on how one poses the question as much as how one 
       answers it."--Publisher's website. 
610 20 Celera Diagnostics. 
610 20 Human Genome Project. 
650  0 Biotechnology industries|zCalifornia. 
650  0 Business anthropology. 
700 1  Dan-Cohen, Talia,|d1982- 
935    .o13651286 
945    338.76606 RABI|i31290024585887|lMME|nVendor Interface 
980    11-30-07|b2331|e2179|f7450186|g1 
984    VU|cheld 
990    Uploaded by DA 
990    Sent to MARCIVE 20190531 
Location Call No. Status
 UniM BioMed  338.76606 RABI    AVAILABLE